ADMA Biologics (NASDAQ:ADMA) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.02), Fidelity Earnings reports. ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $5.39 million.
NASDAQ:ADMA traded down $0.48 during midday trading on Friday, reaching $5.26. 175,312 shares of the stock traded hands, compared to its average volume of 228,164. ADMA Biologics has a 12-month low of $2.10 and a 12-month high of $6.96. The company has a quick ratio of 8.88, a current ratio of 10.65 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $254.46 million, a price-to-earnings ratio of -2.75 and a beta of 2.28.
Several equities research analysts have recently weighed in on ADMA shares. Raymond James reaffirmed a “buy” rating and issued a $10.00 price target (down previously from $11.00) on shares of ADMA Biologics in a research report on Friday, October 12th. Oppenheimer set a $13.00 price target on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Wednesday, October 17th. BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price target on shares of ADMA Biologics in a research report on Wednesday, October 17th. Finally, Chardan Capital started coverage on shares of ADMA Biologics in a research report on Monday, July 30th. They issued a “buy” rating and a $10.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $11.58.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
See Also: Dollar Cost Averaging
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.